Systemic bevacizumab for recurrent respiratory papillomatosis: A national survey

ConclusionsSystemic bevacizumab appears to have significant promise in the most treatment‐resistant and aggressive forms of papillomatosis with a low complication profile. These results suggest bevacizumab should be studied in a formal clinical trial for RRP. Level of Evidence4. Laryngoscope, 2017 (Source: The Laryngoscope)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

from MedWorm via o.lakala70 on Inoreader http://ift.tt/2s2sz2B
via IFTTT